Mitochondrial DNA Mutations in Leigh Syndrome and Their Phylogenetic Implications
Overview
Affiliations
Of 100 patients with the clinical diagnosis of Leigh syndrome, 21 were found to have specific enzyme defects: 15 involving cytochrome c oxidase (COX); 4, pyruvate dehydrogenase complex (PDHC); one, complex I (reduced nicotinamide adenine dinucleotide [NADH]-coenzyme Q reductase) and one, complex II (succinate-ubiquinone reductase) deficiencies. In addition to the most common form of COX deficiency, mtDNA mutations in the adenosine triphosphatase (ATPase) 6 coding region were also commonly seen. Eighteen patients (18%) had mtDNA mutations at nucleotide position (np) 8993 or 9176. The mutated DNAs were present in a heteroplasmic state, comprising more than 90% of the DNA in muscle and/or blood samples from all patients. Patients with the T-to-G mutation at np 8993 usually had early onset of the disease with rapid progression, showing the typical clinical features of Leigh syndrome. On the other hand, those with the T-to-C 8993 mutation showed a milder and more chronic course. Patients with the mutation at np 9176 showed variable courses. Phylogenetic analysis of mtDNA D-loop sequences for the patients with the ATPase 6 mutations and normal Japanese subjects revealed that a T-to-G/C mutation at np 8993 and a T-to-C mutation at np 9176 occurred many times independently in the Japanese population.
Syndromic Retinitis Pigmentosa: A Narrative Review.
Janaky M, Braunitzer G Vision (Basel). 2025; 9(1.
PMID: 39846623 PMC: 11755594. DOI: 10.3390/vision9010007.
A systematic review on the biochemical threshold of mitochondrial genetic variants.
Smith K, Moreira J, Wilson C, Padera J, Lamason A, Xue L Genome Res. 2024; 34(3):341-365.
PMID: 38627095 PMC: 11067886. DOI: 10.1101/gr.278200.123.
Dawod P, Jancic J, Marjanovic A, Brankovic M, Jankovic M, Samardzic J Diagnostics (Basel). 2021; 11(11).
PMID: 34829316 PMC: 8620769. DOI: 10.3390/diagnostics11111969.
Serial cryoFIB/SEM Reveals Cytoarchitectural Disruptions in Leigh Syndrome Patient Cells.
Zhu Y, Sun D, Schertel A, Ning J, Fu X, Gwo P Structure. 2020; 29(1):82-87.e3.
PMID: 33096015 PMC: 7802768. DOI: 10.1016/j.str.2020.10.003.
Mitochondrial DNA heteroplasmy in disease and targeted nuclease-based therapeutic approaches.
Nissanka N, Moraes C EMBO Rep. 2020; 21(3):e49612.
PMID: 32073748 PMC: 7054667. DOI: 10.15252/embr.201949612.